Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsHMSA Remodulin Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentHawaii Medical Service Association (HMSA)Policy N/A

    Remodulin (treprostinil) injection coverage

    Customize your policy alerts

    Sign up for all Hawaii Medical Service Association (HMSA) policy alerts

    Know when Hawaii Medical Service Association (HMSA) releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs HMSA coverage and prior authorization for Remodulin (treprostinil) injection for pulmonary arterial hypertension. It applies to members in the HMO, PPO, and QUEST lines of business when coverage criteria and documentation requirements are met.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyRemodulin (treprostinil) injection coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJun 1, 2026
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain precertification for Remodulin before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    WHO Group 1Covered classification
    >20 mmHg

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Mean pulmonary artery pressure
    ≤15 mmHgPulmonary capillary wedge pressure
    >2 WUPulmonary vascular resistance
    IndefiniteAuthorization duration
    Pulmonologist or cardiologistPrescriber specialty

    Pulmonary Arterial Hypertension Coverage

    Pulmonary arterial hypertension

    Covered with indefinite authorization when all of the following are met.

    PAH coverage criteria

    • WHO Group 1 PAH: Member has pulmonary arterial hypertension (PAH) defined as WHO Group 1 class of pulmonary hypertension.WHO Group 1
    • PAH confirmation pathway

      • Pretreatment right heart catheterization shows mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure of 15 mmHg or less, and pulmonary vascular resistance greater than 2 Wood units. For pediatric members, pulmonary vascular resistance index greater than 3 Wood units × m² is also acceptable.mPAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units; pediatric PVRI >3 Wood units × m² acceptable
      • Infant Doppler alternative: For an infant less than one year of age, PAH is confirmed by Doppler echocardiogram when right heart catheterization cannot be performed.Age <1 year

    Clinical Thresholds and Parameters

    Mean pulmonary arterial pressure
    Required value>20 mmHg
    MeasurementMean pulmonary arterial pressure (mPAP)
    Confirmation pathwayPretreatment right heart catheterization
    Pulmonary capillary wedge pressure
    Required value≤15 mmHg
    MeasurementPulmonary capillary wedge pressure (PCWP)
    Confirmation pathwayPretreatment right heart catheterization

    Authorization and Documentation Requirements

    Prior Authorization

    Precertification Required

    Precertification is required before treatment. Submit the applicable HMSA medical specialty drug fax form through the HMSA precertification process.

    Note

    Specialist Prescriber Required

    The medication must be prescribed by or in consultation with a pulmonologist or cardiologist.

    Documentation Required

    Document Pretreatment Hemodynamics

    Include the pretreatment medical-record report and right heart catheterization results required for prior authorization review. If right heart catheterization cannot be performed in an infant, include Doppler ultrasound findings.

    Policy Background

    Remodulin (treprostinil) injection is covered for the treatment of pulmonary arterial hypertension (PAH), including use to diminish exercise-associated symptoms and, for patients transitioning from epoprostenol, to diminish the rate of clinical deterioration. Under this policy, PAH is defined as WHO Group 1 pulmonary hypertension.

    Coverage requires confirmation of PAH through qualifying pretreatment right heart catheterization showing mPAP >20 mmHg, PCWP ≤15 mmHg, and PVR >2 Wood units. For pediatric members, PVRI >3 Wood units × m² is also acceptable; for infants <1 year of age when right heart catheterization cannot be performed, Doppler echocardiography may be used for confirmation.

    Pulmonary Hypertension Definitions

    Pulmonary arterial hypertension
    TermPulmonary arterial hypertension (PAH)
    ClassificationWHO Group 1 pulmonary hypertension
    Covered conditionTreatment of PAH defined as WHO Group 1 pulmonary hypertension
    Hemodynamic confirmation of PAH
    Mean pulmonary arterial pressure>20 mmHg
    Pulmonary capillary wedge pressure≤15 mmHg
    Pulmonary vascular resistance>2 Wood units; for pediatric members, PVRI >3 Wood units × m² is also acceptable

    Initial Therapy

    Initial therapy

    Indefinite authorization may be granted for initial treatment when all of the following criteria are met.

    Initial PAH therapy criteria

    • WHO Group 1 diagnosis: Member has pulmonary arterial hypertension (PAH) defined as WHO Group 1 class of pulmonary hypertension.WHO Group 1
    • Confirmation method

      • Pretreatment right heart catheterization shows mean pulmonary arterial pressure greater than 20 mmHg, pulmonary capillary wedge pressure of 15 mmHg or less, and pulmonary vascular resistance greater than 2 Wood units. For pediatric members, pulmonary vascular resistance index greater than 3 Wood units × m² is also acceptable.mPAP >20 mmHg; PCWP ≤15 mmHg; PVR >2 Wood units; pediatric PVRI >3 Wood units × m² acceptable

    Continuation Therapy

    Continuation therapy

    Indefinite authorization may be granted for continuation therapy when the coverage criteria in section D are met.

    Continuation of Remodulin therapy: Member has pulmonary arterial hypertension and meets the coverage criteria in section D. This applies to new members and members currently receiving treatment without prior authorization.

    Authorization is indefinite when criteria are met.

    Policy Summary
    PayerHawaii Medical Service Association (HMSA)
    PolicyRemodulin (treprostinil) injection coverage
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateJun 1, 2026
    Last ReviewOct 1, 2025
    Next Review DateN/A
    Key ActionObtain precertification for Remodulin before treatment.
    SourceLink
    On This Page
    Pulmonary Arterial Hypertension CoverageClinical Thresholds and ParametersAuthorization and Documentation RequirementsPolicy BackgroundPulmonary Hypertension DefinitionsInitial TherapyContinuation Therapy
    Pulmonary vascular resistance
    Required value>2 Wood units
    MeasurementPulmonary vascular resistance (PVR)
    Confirmation pathwayPretreatment right heart catheterization
    Pediatric pulmonary vascular resistance index
    Required value>3 Wood units × m²
    MeasurementPediatric pulmonary vascular resistance index (PVRI)
    UseAlso acceptable for pediatric members as part of the pretreatment right heart catheterization criteria
    Infant Doppler echocardiogram alternative
    Age requirementLess than 1 year of age
    Alternative testDoppler echocardiogram
    When applicableWhen right heart catheterization cannot be performed
    • Report pretreatment mean pulmonary artery pressure (mPAP).
    • Report pulmonary capillary wedge pressure (PCWP).
    • Report pulmonary vascular resistance (PVR).
    • For infants unable to undergo right heart catheterization, provide Doppler ultrasound findings.
    Denial Risk

    Denial Risk: PAH Criteria Not Met

    Authorization may be denied when the member does not have WHO Group 1 pulmonary arterial hypertension (PAH) or when PAH is not confirmed through the required hemodynamic or pediatric diagnostic pathway.

    • Required confirmation is pretreatment right heart catheterization showing mPAP > 20 mmHg, PCWP ≤ 15 mmHg, and PVR > 2 Wood units.
    • For pediatric members, PVRI > 3 Wood units × m² is also acceptable.
    • For infants younger than one year when right heart catheterization cannot be performed, confirmation may be by Doppler echocardiogram.
    Denial Risk

    Denial Risk: Specialist or Precertification Requirements

    Authorization may be denied if the medication is not prescribed by or in consultation with a pulmonologist or cardiologist, or if the required precertification and HMSA medical specialty drug fax form are not completed.

    • Ensure specialist prescriber or consultation involvement is documented.
    • Complete the HMSA precertification process and submit the applicable medical specialty drug fax form before treatment.
    WHO classification of pulmonary hypertension
    Group 1Pulmonary arterial hypertension (PAH)
    Group 2Pulmonary hypertension associated with left heart disease
    Group 3Pulmonary hypertension associated with lung diseases and/or hypoxia
    Group 4Pulmonary hypertension associated with pulmonary artery obstructions
    Group 5Pulmonary hypertension with unclear and/or multifactorial mechanisms
    Infant Doppler echocardiogram: The infant is less than one year of age, right heart catheterization cannot be performed, and PAH is confirmed by Doppler echocardiogram.Age <1 year